Group 1 - Johnson & Johnson is focusing on innovative cancer drugs and medical devices, particularly in cardiovascular care, as highlighted by CEO Joaquin Duato [1][2] - The company is currently facing talc lawsuits, but there is a belief that the risk from asbestos and baby powder litigation has peaked, with J&J winning several cases [1] - J&J plans to continue fighting the lawsuits individually, with expectations that plaintiffs may eventually find it too costly to pursue [1] Group 2 - Johnson & Johnson develops a wide range of pharmaceuticals and medical technologies, including areas such as immunology, oncology, and cardiovascular care [2]

Welcome back to Market on Close. Shares of Johnson and Johnson hit a new all-time high today after Wells Fargo upgraded the stock to overweight from equal weight and raised its price target to $212 from $170. The firm says it sees potential upside to J&J's pharma business and lowered tariff and pricing risks.Wells Fargo said the stock's valuation presents an attractive entry point right now. So now it's time for Options Corner. Joining us is Rick Dukat, our lead market technician here on Schwab Network to t ...

U.S. stock market surged to record highs on Friday. The Dow rose 366 points to 46,238, the S&P 500 gained 0.4% to 6,823, and the The gains put the indexes on track for a positive week. The S&P 500 and Dow are up more than 1% week to date. The Nasdaq has risen nearly 2%, and the Russell 2000 is up 2.4%. Investors remain confident that the government shutdown, now in its third day, will be short-lived. Historically, shutdowns have not significantly affected market momentum. The shutdown has paused economic r ...

Investors with a lot of money to spend have taken a bearish stance on Johnson & Johnson (NYSE:JNJ).And retail traders should know.We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with JNJ, it often means somebody knows something is about to happen.So how do we know what these investors just did? Today, Benzinga's options scanner sp ...

格隆汇10月3日｜道指涨幅扩大至1%，再创历史新高。成分股中，强生涨近2%亦创历史新高。 ...

每经AI快讯，10月3日，道指涨幅扩大至1%，再创历史新高。成分股中，强生涨近2%，股价创历史新 高。联合健康涨超3%。 （文章来源：每日经济新闻） ...

（文章来源：每日经济新闻） 每经AI快讯，10月3日，强生公司股价创下历史新高，最新上涨1.8%。 ...

Upgrades - Rothschild & Co Redburn upgraded Coinbase (COIN) to Buy from Neutral with a price target of $417, increased from $325, expecting retail volume growth to mitigate take rate compression [2] - Wells Fargo upgraded Johnson & Johnson (JNJ) to Overweight from Equal Weight with a price target of $212, up from $170, indicating that concerns around pharmaceutical tariffs and pricing risks are largely resolved [3] - Gordon Haskett upgraded Zillow (Z) to Buy from Hold with a price target of $90, citing favorable risk/reward due to negative sentiment affecting shares [3] - Fox Advisors upgraded Instacart (CART) to Outperform from Equal-Weight, believing the 24% decline in stock price since August 11 is "oversold" due to overblown competitive concerns [3] - Erste Group upgraded Alibaba (BABA) to Buy from Hold, noting the company's strong development in artificial intelligence applications [4] Downgrades - Jefferies downgraded Apple (AAPL) to Underperform from Hold with a price target of $205.16, down from $205.82, citing excessive expectations on the replacement cycle and prospects of the iPhone 18 Fold [5] - Piper Sandler downgraded Instacart (CART) to Neutral from Overweight with a price target of $41, down from $62, due to rising competitive pressures from major players like Amazon and Walmart [5] - Wolfe Research downgraded PayPal (PYPL) to Peer Perform from Outperform, with a fair value range of $70-$80, indicating shares may be range-bound until further proof of execution is shown [5] - KeyBanc downgraded Corteva (CTVA) to Sector Weight from Overweight without a price target, following the company's announcement to separate into two public companies [5] - Goldman Sachs downgraded Bumble (BMBL) to Neutral from Buy with a price target of $7, down from $8, stating that the stock's risk/reward is more balanced at current levels [5]

Retirees and older individuals are among the biggest demographics who tune into Jim Cramer's Mad Money show. ...

Group 1 - Boeing's new 777X widebody jet commercial debut is delayed to early 2027, potentially leading to significant non-cash accounting charges due to prolonged safety certification work [1] - BlackRock's Global Infrastructure Partners is negotiating to acquire Aligned Data Centers for approximately $40 billion, following a nearly $38 billion takeover of AES [1] - Johnson & Johnson was upgraded to buy from hold at Wells Fargo, with analysts optimistic about its cancer franchise and the removal of existential risks related to tariffs and drug pricing [1] Group 2 - Constellation Brands' price target was reduced to $175 from $205 by UBS, although the stock maintains a buy rating, trading at over 11 times forward earnings with a 2.9% dividend yield [1] - UBS maintains a sell rating on Tesla despite better-than-expected third-quarter deliveries, citing concerns over demand pull-forward due to EV tax credit expiration [1] - AeroVironment received price target increases to $400 and $415 from Citizens JMP and BTIG, both maintaining buy ratings and expressing strong bullish sentiment [1] Group 3 - KeyBanc downgraded Corteva to hold from buy following its announcement to split into two companies, raising concerns about the impact of breakups on stock performance [1] - Citi analysts proposed a three-way merger involving CSX, Canadian Pacific Kansas City, and Berkshire Hathaway-owned BNSF as a strategic response to the Union Pacific and Norfolk Southern merger [1] - Barclays lowered its price target on PepsiCo to $140 from $144, expressing caution ahead of earnings, particularly regarding sales and margins [1]